Diabetes in Africa: A Growing Public Health Crisis

Understand the dynamics behind the rise of diabetes in Africa, from the influence of societal change to the capacity of its health systems to respond.

Diabetes is expanding across Africa faster than on any other continent, and most people who have it don’t know. Roughly three out of four African adults with diabetes remain undiagnosed, the highest proportion of any world region. The continent’s health systems, built largely around infectious diseases, are struggling to absorb a chronic condition that demands lifelong monitoring, medication, and behavioral change. What makes the crisis distinct is not just the numbers but the collision of rapid urbanization, persistent malnutrition, infectious disease epidemics, and health system gaps that together create a problem unlike what higher-income regions have faced.

How Big the Problem Already Is

Surveys across sub-Saharan Africa put the median diabetes prevalence at about 5%, with individual countries ranging from 2% to 14% depending on urbanization, age structure, and screening methods used. Those numbers sound modest compared to the Middle East or North America, but they are climbing steeply, and the real burden is almost certainly much higher because so many cases go undetected. According to recent estimates from the International Diabetes Federation’s 2025 atlas, Africa has the world’s highest share of undiagnosed diabetes at nearly 73%, compared with about 29% in North America and the Caribbean. Systematic reviews focused specifically on the continent consistently confirm this pattern, with Western Africa appearing to carry an even heavier share of hidden cases than the rest of the region.

The practical consequence of so much undiagnosed disease is that many people’s first encounter with diabetes comes through a complication: a wound that won’t heal, sudden vision loss, or a hospitalization for dangerously high blood sugar. By that point, the window for simple lifestyle changes or inexpensive oral medication has often closed.

Why Diabetes Is Surging

Africa is in the middle of a rapid and uneven epidemiological shift. As cities grow, diets tilt toward processed foods, physical activity drops, and overweight and obesity rates rise. The median prevalence of overweight or obesity in the same surveys that measured diabetes was about 27%, with some populations approaching 70%. Diabetes prevalence is highest among urban Africans, and the gap between urban Africa and the African diaspora living in high-income countries is narrowing fast.

But urbanization is only half the story. A less intuitive driver is early-life malnutrition. Research in Ethiopia found that a history of childhood malnutrition was associated with more than a fivefold increase in the odds of developing insulin-requiring diabetes later, alongside markers of poverty like poor sanitation and limited access to clean water. A multi-country study spanning Africa and Asia confirmed that children hospitalized for severe wasting before age two showed higher blood sugar levels when tested years later. The implication is uncomfortable: the same populations that survived hunger as children are now, as adults entering a more food-abundant environment, at heightened risk of developing diabetes. This “double burden” of malnutrition is a defining feature of Africa’s diabetes landscape.

Diabetes Types That Don’t Fit the Textbook

Standard medical training divides diabetes into two neat categories: type 1 (autoimmune, typically juvenile onset, always insulin-dependent) and type 2 (metabolic, adult onset, often manageable without insulin early on). African populations present forms that blur this boundary, and misclassifying them leads to wrong treatment decisions.

The most studied of these is ketosis-prone type 2 diabetes, sometimes called “Flatbush diabetes” after the New York neighborhood where it was first described in detail. It hits like type 1, with sudden, severe metabolic crisis requiring emergency insulin. But after stabilization, roughly three-quarters of patients can stop insulin therapy and enter remission, something essentially unheard of in true type 1 disease. The condition shows a strong male predominance, tends to appear in people over 30 who are normal weight or overweight, and lacks the autoimmune markers associated with type 1. Despite remission, progressive worsening of blood sugar eventually triggers relapses, and about half of patients become permanently insulin-dependent within a decade.

Another distinct subtype is malnutrition-related diabetes, linked to a persistent history of undernutrition and characterized by very low body weight, severe loss of insulin-producing capacity, and a resistance to the ketosis episodes that define type 1. These subtypes matter clinically because treatment protocols designed around European and North American population data can mistreat them. A patient with ketosis-prone type 2 diabetes kept on lifelong insulin unnecessarily faces real costs and risks; a patient with malnutrition-related diabetes given only oral drugs may not respond.

Genetics Built on a Narrow Foundation

Most of what geneticists know about diabetes risk comes from studies of European and East Asian populations. The first large genome-wide association study focused on type 2 diabetes in Africa identified genetic signals that are entirely absent in non-African groups. One variant near a gene called AGMO was strongly linked to type 2 diabetes risk but is essentially nonexistent in most other populations. The well-known TCF7L2 locus, which carries the strongest common-variant risk for type 2 diabetes worldwide, also turned up an African-specific signal distinct from the one found in Europeans. These findings suggest that risk-prediction tools built from European genetic data will miss a meaningful portion of diabetes risk in African populations. The broader lesson is that genomic diversity in Africa, the most genetically diverse continent, remains drastically underrepresented in the research that guides clinical decisions globally.

Collisions with HIV and Tuberculosis

Africa’s diabetes crisis does not exist in isolation. It collides with the continent’s massive HIV and tuberculosis epidemics, and the interactions go in both directions. A study spanning 44 sub-Saharan African countries found that diabetes prevalence among people living with HIV was nearly six percentage points higher than among those without HIV, with antiretroviral therapy itself contributing to that gap. Specific antiretroviral drugs appear to carry their own metabolic risks: one cohort study found that efavirenz, a widely used medication, was associated with a roughly 27% higher hazard of developing diabetes compared with an alternative drug in the same class. In an Ethiopian cohort, older age, certain antiretroviral regimens, and a body mass index over 25 all independently predicted comorbidity of HIV with diabetes and hypertension.

The tuberculosis-diabetes overlap is equally troubling. When the two conditions co-occur, outcomes for both worsen: TB is harder to treat and more likely to recur, while blood sugar becomes more difficult to control. This convergence is expected to grow as both diseases expand, and researchers have called for routine two-way screening, testing every TB patient for diabetes and every diabetes patient for TB, to catch co-infections early.

Complications That Arrive Late and Hit Hard

Because so many cases are caught late, complications are already advanced by the time a person receives a diagnosis. Diabetic foot ulcers illustrate this vividly. A meta-analysis found that about 13% of African diabetes patients develop foot ulcers, and that figure has been rising since the early 2000s. Roughly 15% of those with foot lesions underwent major amputation, and about 14% died during hospitalization. A separate pooled estimate put the share of all amputations in sub-Saharan Africa attributable to diabetes at roughly 37%. These outcomes are compounded by multidrug-resistant infections: in studies reporting clinical outcomes, amputation rates in the presence of resistant bacteria ranged from 15% to 38%, with mortality between 7% and 16%.

Eye damage is another major burden. A meta-analysis of studies across sub-Saharan Africa estimated that about one in four people with diabetes has diabetic retinopathy, with rates highest in East Africa (around 32%) and lowest in Central Africa (around 14%). A separate pooled estimate for East African countries specifically put the figure at 28%, with older age, higher body mass, and poor blood-sugar control all predicting higher risk. In South Africa, screening for retinopathy is essentially nonexistent at the primary care level. A study testing artificial intelligence-based screening at a community health center found that AI flagged retinopathy in about 23% of diabetes patients, compared with 16% identified by an optometrist, suggesting that technology could fill the specialist gap.

The Financial Toll on Families

Diabetes is expensive to manage anywhere. In sub-Saharan Africa, where health insurance coverage is thin and most spending comes directly out of patients’ pockets, the financial weight falls hardest on those who can least absorb it. Annual costs for managing uncomplicated type 2 diabetes range from about $340 for basic medical care to over $2,300 per patient when total provider costs are counted, with the poorest patients shouldering a disproportionate share. Out-of-pocket expenses are a major barrier to getting care at all, and in some settings the largest single cost component is just getting to the clinic: a study in Eswatini found that transport was the biggest chunk of direct spending per visit. When out-of-pocket costs push past a critical threshold, families face what health economists call catastrophic expenditure, spending so much on healthcare that it drives them into poverty.

Why Health Systems Are Not Keeping Up

Most African health systems were designed to fight acute infections, deliver vaccines, and manage maternal and child health. Chronic disease management requires a fundamentally different approach: regular follow-up, continuous medication supply, laboratory monitoring, and patient education over years. The mismatch is stark. A review of the barriers across the region catalogs inadequate infrastructure, severe workforce shortages, fragmented care coordination, missing standardized guidelines, and inefficient governance for chronic conditions. These are structural problems, not easily fixed by a single policy change.

Essential medications and diagnostic tools are frequently unavailable. A review of access across the continent found that the availability of five essential diabetes medicines and three basic diagnostic tests was suboptimal, with insulin and tests like HbA1c and lipid profiles priced beyond what many patients can afford. Kenya offers a case study in the structural friction: stakeholders there identified a disconnect between national policy and what actually happens at clinics, donor-driven funding priorities that sideline chronic disease, limited collaboration between agencies, and a “siloed” mindset that keeps infectious and chronic disease programs from sharing resources.

Traditional Medicine and Undisclosed Use

Across Africa, traditional medicine plays a major role in how people manage diabetes, whether or not their doctors know about it. A systematic review found that the share of diabetes patients using traditional remedies ranged from about 12% to 77%, with a median of 50%. Most users took herbal or traditional preparations alongside their prescribed medications, and the vast majority, between 64% and 91%, did not tell their healthcare providers. The concern is not that all traditional remedies are harmful; some may have genuine pharmacological activity. The concern is that undisclosed concurrent use creates risk of herb-drug interactions, unpredictable blood sugar swings, and abandonment of proven treatments. Clinicians who don’t ask about traditional medicine are effectively flying blind for up to half their patients.

Cultural Norms Around Body Size

Weight management is central to preventing and controlling type 2 diabetes, but in many African communities the conversation runs into deeply embedded cultural values. Research in Benin found that larger body sizes, especially for women, are associated with health, fertility, respect, and social standing. Women face pressure to gain weight after pregnancy, and weight loss can trigger concern from partners and family rather than encouragement. Public health messaging that frames weight loss as universally desirable can clash with these norms, making it less effective or even counterproductive. Effective programs need to navigate this cultural terrain rather than ignore it.

Approaches That Show Promise

Despite the scale of the problem, real solutions are emerging. Community health workers, already the backbone of HIV and maternal health programs in many countries, are being trained to screen for diabetes and hypertension in the community and refer people to clinics. A qualitative study in rural Uganda found that both patients and professionals viewed task-shifting of screening duties to community health workers as practical and acceptable, though it requires adequate training, supervision, and supply chains to succeed.

Lifestyle interventions adapted to local contexts are also showing results. A program called Lifestyle Africa, modeled on the well-known diabetes prevention approach used in the United States but delivered by community health workers in an under-resourced South African community, produced meaningful improvements in HbA1c (a key marker of blood sugar control) at a cost of about $71 per participant. Mobile health technology is another avenue. An app called DiabAid Nexus, developed and tested with diabetes patients in Ethiopia, scored high on usability and information quality, with users appreciating its localized content and intuitive design. Given how rapidly mobile phone access is expanding across Africa, app-based self-management support could eventually reach patients that the formal health system cannot.

At the policy level, South Africa became the first African country to impose a tax on sugar-sweetened beverages, in 2018. Modeling of the tax’s impact estimated a 16% reduction in diabetes cases in a younger cohort (age 35) and a 6% reduction in an older cohort (age 40). Whether other African nations follow suit could shape the trajectory of diabetes across the continent in the coming decades.

Gestational Diabetes and the Next Generation

The crisis extends into pregnancy. A systematic review and meta-analysis found a high burden of gestational diabetes in sub-Saharan Africa, with obesity among older mothers standing out as a key risk factor. Gestational diabetes doesn’t just endanger the current pregnancy; it substantially raises the mother’s lifetime risk of developing type 2 diabetes afterward, and it can influence the metabolic health of the child. In settings where antenatal screening for diabetes is patchy, many cases go undetected, and the cycle continues into the next generation. The evidence linking childhood malnutrition to later diabetes risk, combined with the rising rates of gestational diabetes, means that Africa faces a compounding problem: today’s undetected cases may be seeding tomorrow’s epidemic both through metabolic programming in utero and through the structural poverty that keeps families from accessing care.